Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Cash & Current Investments (2018 - 2025)

China SXT Pharmaceuticals has reported Cash & Current Investments over the past 8 years, most recently at $21.2 million for Q3 2025.

  • For Q3 2025, Cash & Current Investments rose 14.5% year-over-year to $21.2 million; the TTM value through Sep 2025 reached $21.2 million, up 14.5%, while the annual FY2025 figure was $18.1 million, 50.11% up from the prior year.
  • Cash & Current Investments for Q3 2025 was $21.2 million at China SXT Pharmaceuticals, up from $18.1 million in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $31.3 billion in Q3 2021 and troughed at $3.0 million in Q3 2022.
  • A 5-year average of $3.1 billion and a median of $16.5 million in 2022 define the central range for Cash & Current Investments.
  • Biggest five-year swings in Cash & Current Investments: skyrocketed 302416.82% in 2021 and later crashed 99.99% in 2022.
  • Year by year, Cash & Current Investments stood at $31.3 billion in 2021, then crashed by 99.99% to $3.0 million in 2022, then surged by 284.6% to $11.5 million in 2023, then surged by 61.47% to $18.5 million in 2024, then grew by 14.5% to $21.2 million in 2025.
  • Business Quant data shows Cash & Current Investments for SXTC at $21.2 million in Q3 2025, $18.1 million in Q1 2025, and $18.5 million in Q3 2024.